Theseus Pharmaceuticals Investor Relations

News Releases

Month Year

Investor Alerts

May 31, 2023

Theseus Pharmaceuticals to Participate in the Jefferies Healthcare Conference
May 25, 2023

Theseus Pharmaceuticals Reports Initial Dose Escalation Data from Ongoing Phase 1/2 Trial of THE-630 in Patients with Advanced GIST
May 11, 2023

Theseus Pharmaceuticals Announces Business Highlights and Reports First Quarter 2023 Financial Results
Apr 26, 2023

Theseus Pharmaceuticals Initial Dose Escalation Results from Ongoing Phase 1/2 Trial of THE-630 Accepted for Online Publication at 2023 ASCO Annual Meeting
Apr 11, 2023

Theseus Pharmaceuticals to Participate in Upcoming Investor Conferences
Mar 28, 2023

Theseus Pharmaceuticals to Participate in the Cantor Future of Oncology Virtual Symposium
Mar 9, 2023

Theseus Pharmaceuticals Announces Business Highlights and Reports Fourth Quarter and Full Year 2022 Financial Results
Feb 7, 2023

Theseus Pharmaceuticals to Participate in the SVB Securities Global Biopharma Conference
Jan 5, 2023

Theseus Pharmaceuticals Highlights Key Anticipated 2023 Milestones and Announces BCR-ABL as Target for Third Development Program
Nov 3, 2022

Theseus Pharmaceuticals Announces Business and Pipeline Highlights and Reports Third Quarter 2022 Financial Results
Oct 26, 2022

Theseus Pharmaceuticals Presents Preclinical Data Characterizing THE-349, its Fourth-Generation EGFR Inhibitor in Development for NSCLC, at the 34th EORTC-NCI-AACR Symposium
Oct 19, 2022

Theseus Pharmaceuticals Appoints Steven Stein, M.D. to Board of Directors
Oct 3, 2022

Theseus Pharmaceuticals Nominates THE-349, a Fourth-Generation EGFR Inhibitor Development Candidate in Non-Small Cell Lung Cancer
Sep 6, 2022

Theseus Pharmaceuticals to Participate at Upcoming September Investor Conferences
Aug 11, 2022

Theseus Pharmaceuticals Announces Business and Pipeline Highlights and Reports Second Quarter 2022 Financial Results
Aug 3, 2022

Theseus Pharmaceuticals to Participate Virtually in Wedbush PacGrow Healthcare Conference
May 19, 2022

Theseus Pharmaceuticals to Participate in Upcoming Investor Conferences
May 18, 2022

Theseus Pharmaceuticals Appoints Don Hayden to Board of Directors
May 12, 2022

Theseus Pharmaceuticals Announces Business Highlights and Reports First Quarter 2022 Financial Results
Apr 8, 2022

Theseus Pharmaceuticals Announces Preclinical Data Characterizing Next-Generation Epidermal Growth Factor Receptor (EGFR) Inhibitors at the 2022 American Association for Cancer Research (AACR) Annual Meeting
Apr 5, 2022

Theseus Pharmaceuticals to Participate Virtually in Needham Healthcare Conference
Mar 10, 2022

Theseus Pharmaceuticals Announces Business Highlights and Reports Fourth Quarter and Full Year 2021 Financial Results

Patient enrollment underway in Phase 1/2 clinical trial in patients with advanced gastrointestinal stromal tumors (GIST)
Mar 8, 2022

Theseus Pharmaceuticals to Present Preclinical Data Characterizing Next-Generation Epidermal Growth Factor Receptor (EGFR) Inhibitors at the 2022 American Association for Cancer Research (AACR) Annual Meeting
Feb 9, 2022

Theseus Pharmaceuticals to Participate Virtually in SVB Leerink Global Healthcare Conference
Feb 2, 2022

Theseus Pharmaceuticals Receives U.S. FDA Orphan Drug Designation for THE-630 for the Treatment of Advanced Gastrointestinal Stromal Tumors (GIST)

Show per page